Seminars | This Week

CIDR Forum

Date/Time: Friday 28th July 2017 10:00

Location: Large Seminar Room, QBP

Title of talk: Innate immunity and inflammasome responses to intracellular pathogens and cancer
Speaker's name: Dr Si Ming Man
Speaker's organisation: Australian National University

Host name: Kate Schroder
Host email: k.schroder@imb.uq.edu.au

Seminars | This Week

IMB Chemistry and Structural Biology Division Seminar

Date/Time: Thursday 27th July 2017 12:30

Location: Seminar Room 3.142, QBP Bldg 80, UQ St Lucia

Title of talk: Potent, selective and oral CDK inhibitors for treating cancers
Speaker's name: Professor Shudong Wang
Speaker's organisation: University of South Australia
Talk abstract: Cyclin-dependent kinases (CDKs) are deregulated in majority of cancers. The earlier generation of CDK inhibitors were non-specific, and toxicities have hampered their utilization. More recently, CDK4/6 inhibitors - palbociclib and ribociclib have received the regulatory approval for the treatment of metastatic breast cancer. This has fuelled significant research efforts to exploit CDKs for the development of the next generation of cancer therapies. In this talk, I will look at the identification of our drug candidates that target the individual CDK4, CDK6 and CDK9 for treating haematological cancer and solid tumour. I will discuss the drug target rationale, anti-cancer mechanisms, and preclinical drug development.

Host name: Professor David Fairlie
Host email: d.fairlie@imb.uq.edu.au

Seminars | This Week

Cell Biology Forum

Date/Time: Wednesday 26th July 2017 09:00

Location: Large Seminar Room QBP Building

Title of talk: TBA
Speaker's name: Wooram Yung
Speaker's organisation: IMB, UQ (Parton lab)

Host name: Brett Collins
Host email: b.collins@imb.uq.edu.au

Seminars | This Week

QBI Neuroscience Seminar

Date/Time: Monday 24th July 2017 11:00

Location: QBI Auditorium

Title of talk: Rewiring the circuits of high acuity spatial vision
Speaker's name: Professor Sunil Gandhi
Speaker's organisation: Department of Neurobiology and Behaviour School of Biological Sciences University of California
Talk abstract: In the visual circuits of the cerebral cortex, the maturation of a small population of inhibitory neurons has been linked to both the opening and closing of a critical period for binocular vision. We have discovered that the transplantation of embryonic inhibitory neurons into adult mouse visual cortex creates a new critical period for binocular vision. Functional imaging of transplanted interneurons reveals that these cells wire into the host visual system following an intrinsically determined developmental program. The transplanted inhibitory neurons reactivate juvenile cortical plasticity when the donor animal's critical period would have occurred. We find in both neurophysiological and behavioral experiments that transplantation completely reverses visual acuity deficits in mice deprived of normal vision during development. We hypothesize that transplanted cells reactivate critical period plasticity by contributing a short-lived disinhibitory microcircuit to the host visual cortex. I will discuss evidence that inhibitory circuits respond rapidly to visual deprivation and that the disinhibition depends critically on Neuregulin-1/ErbB4 signaling, a key pathway implicated in schizophrenia. I will conclude my talk by presenting some new insights we have gained into the organization of binocularity and high spatial acuity in the mouse visual pathway that challenges our basic assumptions. Our transplantation experiments open up a new avenue for understanding the mechanisms of juvenile brain plasticity. Furthermore, our approach to reactivating juvenile plasticity in the adult cortex may lead to novel therapeutics for brain injury, neurodegeneration and neurodevelopmental disorders such as schizophrenia.

Host name: Charmaine Paiva
Host email: m.paiva@uq.edu.au

Seminars | This Week

SCMB Seminar

Date/Time: Wednesday 26th July 2017 12:00

Location: AIBN Seminar Room

Title of talk: Why) is immune memory to pertussis failing and what can we do about it?
Speaker's name: Dimitri A. Diavatopoulos
Speaker's organisation: Radboud Center for Infectious Diseases, Radboud university
Talk abstract: Despite the availability of effective prophylactic vaccines against pertussis, there has been a rise in the incidence of pertussis, with recent epidemics occurring in the last decades in Europe, the US and Australia. As well as being a particular problem in vulnerable infants, with devastating consequences in developing countries, the incidence of pertussis is also increasing in adolescents and adults, particularly in high-income countries. Evidence suggests that immunity in humans wanes rapidly after primary immunization with pertussis vaccines, especially with the acellular pertussis vaccines (aPs) predominantly used in high-income countries. This suggests that the improvements in the safety profile of aPs, as compared to whole cell pertussis vaccines (wPs), may be accompanied by differences in the elicited immune response and a reduction in long-term effectiveness. Changes have also been observed in circulating Bordetella pertussis strains, culminating in the recent emergence and expansion of vaccine antigen-deficient strains, in particular pertactin-deficient strains.

Studies in the recently established baboon model have demonstrated that aPs prevent severe disease but do not prevent asymptomatic infection, i.e. colonization, or transmission to naive animals, whereas infection and to some extent wPs can prevent colonization and transmission and disease. Although a role of functional antibodies and T cell responses in protection against disease and/or carriage has been demonstrated, there are still important knowledge gaps, in particular relating to human immunity to B. pertussis and whether observations in animal models translate to clinical practice. This paucity of knowledge hampers the development and registration of improved vaccines and the design of better vaccination strategies against pertussis in infants, adolescents and adults. The development and licensing of the next generation of improved vaccines depends on 1) a more thorough understanding of immune response to infection 2) identification of immunological correlates of protection and 3) the development of human and animal models as well as bioassays to predict and evaluate vaccine efficacy.

Host name: Nick West
Host email: n.west@uq.edu.au